Therapeutic Potential of Plant Secondary Metabolites in the Treatment of Diseases and Drug Development
The importance of natural products, and especially plant secondary metabolites, for the treatment of diseases and drug development has already been obvious in medicine for several thousand years. Thus, this Special Issue of MDPI Biomedicines collects eight top articles from the field as regular full...
Saved in:
| Sonstige: | |
|---|---|
| Year of Publication: | 2022 |
| Language: | English |
| Physical Description: | 1 electronic resource (334 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 04360nam-a2201369z--4500 | ||
|---|---|---|---|
| 001 | 993545217904498 | ||
| 005 | 20231214133238.0 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 202207s2022 xx |||||o ||| 0|eng d | ||
| 035 | |a (CKB)5690000000012059 | ||
| 035 | |a (oapen)https://directory.doabooks.org/handle/20.500.12854/87430 | ||
| 035 | |a (EXLCZ)995690000000012059 | ||
| 041 | 0 | |a eng | |
| 100 | 1 | |a Drašar, Pavel B. |4 edt | |
| 245 | 1 | 0 | |a Therapeutic Potential of Plant Secondary Metabolites in the Treatment of Diseases and Drug Development |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
| 300 | |a 1 electronic resource (334 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 520 | |a The importance of natural products, and especially plant secondary metabolites, for the treatment of diseases and drug development has already been obvious in medicine for several thousand years. Thus, this Special Issue of MDPI Biomedicines collects eight top articles from the field as regular full papers in addition to five reviews. All of the published papers are a vibrant source of information on the therapeutic potential of plant secondary metabolites in the treatment of diseases and drug development. | ||
| 546 | |a English | ||
| 650 | 7 | |a Technology: general issues |2 bicssc | |
| 650 | 7 | |a Chemical engineering |2 bicssc | |
| 653 | |a Cannabis sativa (Cannabis) | ||
| 653 | |a cannabinoids | ||
| 653 | |a tetrahydrocannabinol (THC) | ||
| 653 | |a cannabidiol (CBD) | ||
| 653 | |a cannabinoid receptors (CB1 and CB2) | ||
| 653 | |a Papaver somniferum (opium poppy) | ||
| 653 | |a secondary metabolites | ||
| 653 | |a ursolic acid | ||
| 653 | |a NSCLC | ||
| 653 | |a tumorsphere | ||
| 653 | |a EGFR | ||
| 653 | |a STAT3 | ||
| 653 | |a MMP2 | ||
| 653 | |a PD-L1 | ||
| 653 | |a MAFLD | ||
| 653 | |a tanshinone IIA | ||
| 653 | |a phytochemical | ||
| 653 | |a lipogenesis | ||
| 653 | |a lipid accumulation | ||
| 653 | |a LXRα | ||
| 653 | |a malaria | ||
| 653 | |a quinine | ||
| 653 | |a chloroquine | ||
| 653 | |a artemisinin | ||
| 653 | |a onchocerciasis | ||
| 653 | |a ivermectin | ||
| 653 | |a moxidectin | ||
| 653 | |a cancer | ||
| 653 | |a vincristine | ||
| 653 | |a vinblastine | ||
| 653 | |a anabolic | ||
| 653 | |a diabetes | ||
| 653 | |a Duchenne muscular dystrophy | ||
| 653 | |a β-ecdysone | ||
| 653 | |a ecdysteroid | ||
| 653 | |a ecdysterone | ||
| 653 | |a Mas1 | ||
| 653 | |a osteoporosis | ||
| 653 | |a sarcopenia | ||
| 653 | |a COVID-19 | ||
| 653 | |a cardiometabolic diseases | ||
| 653 | |a respiratory diseases | ||
| 653 | |a natural product | ||
| 653 | |a SARS-CoV-2 | ||
| 653 | |a lung cancer | ||
| 653 | |a United States Food and Drug Administration-approved drug | ||
| 653 | |a natural remedy | ||
| 653 | |a triterpenoid | ||
| 653 | |a molecular ribbon | ||
| 653 | |a Huisgen 1,3-dipolar cycloaddition | ||
| 653 | |a amide bond | ||
| 653 | |a multifunctional PEG3 derivative | ||
| 653 | |a antimicrobial activity | ||
| 653 | |a anti-HIV activity | ||
| 653 | |a cytotoxicity | ||
| 653 | |a supramolecular self-assembly | ||
| 653 | |a phytocannabinoids | ||
| 653 | |a cannabichromene | ||
| 653 | |a thermos-TRPs | ||
| 653 | |a TRPA1 | ||
| 653 | |a α,α-dimethylheptyl effect | ||
| 653 | |a betulinic acid | ||
| 653 | |a BODIPY | ||
| 653 | |a bevirimat | ||
| 653 | |a cell-cycle | ||
| 653 | |a fluorescent microscopy | ||
| 653 | |a maturation inhibitor | ||
| 653 | |a capsaicinoids | ||
| 653 | |a endocannabinoidome | ||
| 653 | |a microbiota | ||
| 653 | |a overweight | ||
| 653 | |a obesity | ||
| 653 | |a food intake | ||
| 653 | |a lipidomics | ||
| 653 | |a metabolism | ||
| 653 | |a alkaloids | ||
| 653 | |a membrane fusion | ||
| 653 | |a viral fusion inhibitor | ||
| 653 | |a antiviral therapy | ||
| 653 | |a curcumin | ||
| 653 | |a cancer cells | ||
| 653 | |a bioavailability | ||
| 653 | |a curcumin derivatives | ||
| 653 | |a curcumin analogues | ||
| 653 | |a curcumin delivery systems | ||
| 653 | |a natural product synthesis | ||
| 653 | |a lignans | ||
| 653 | |a inflammation | ||
| 653 | |a NF-κB inhibition | ||
| 776 | |z 3-0365-3881-X | ||
| 776 | |z 3-0365-3882-8 | ||
| 700 | 1 | |a Drašar, Pavel B. |4 oth | |
| 906 | |a BOOK | ||
| ADM | |b 2023-12-15 05:47:37 Europe/Vienna |f system |c marc21 |a 2022-07-14 08:50:39 Europe/Vienna |g false | ||
| AVE | |i DOAB Directory of Open Access Books |P DOAB Directory of Open Access Books |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337877990004498&Force_direct=true |Z 5337877990004498 |b Available |8 5337877990004498 | ||